Leukemia and Lymphoma Shares Latest News On Chronic Myelogenous Leukemia
Chronic Myelogenous Leukemia
An expert on leukemia, will discuss novel treatment approaches for chronic myelogenous leukemia (CML) in a free telephone workshop entitled The Latest on CML.
The program is scheduled for Thursday, Jun. 28, 2007, 12:00 p.m. - 1:30 p.m. ET.
Dr. Shah, assistant professor for the division of Hematology/Oncology Department of Medicine at the UCSF School of Medicine in San Francisco, CA., will discuss treatment choices, emerging CML therapies, the role of clinical trials and quality of life issues. A question-and-answer period will follow.
"This program provides an excellent opportunity to hear about the latest information coming out of ASCO from a medical expert," explains Robin Kornhaber, M.S.W., the Society's senior vice president of patient services. "We encourage patients, caregivers and healthcare providers to participate in this informative program."
The program is approved for 1.5 Continuing Education Unit for nurses and social workers upon verification of completion. The program is being offered by The Leukemia & Lymphoma Society, the leading source of information and support for patients battling leukemia, lymphoma and myeloma, and is supported by an unrestricted grant from Bristol-Myers Squibb.
CML results from an acquired (not inherited) injury to the DNA of a stem cell in the marrow. This injury is not present at birth. Scientists do not yet understand what produces this change in the DNA of CML patients, but the resultant marker of CML cells, the Philadelphia chromosome, is well-understood and this has led to significant treatment advances over the last several years.
This change in the stem cell's DNA confers a growth and survival advantage on the malignant stem cell. The result of this injury is the uncontrolled growth of white cells leading, if unchecked, to a massive increase in their concentration in the blood. Unlike acute myelogenous leukemia, chronic myelogenous leukemia permits the development of mature white blood cells and platelets that generally can function normally. This important distinction from acute leukemia accounts for the less severe early course of the disease.
The estimated number of CML cases in the United States is 4,500. Of the 35,070 newly diagnosed leukemia cases in the United States this year. There will be an estimated 600 deaths from CML this year.
The Leukemia & Lymphoma Society, headquartered in White Plains, NY, with 66 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The Society's mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, the Society has invested more than $486 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, the Society made 4.2 million contacts with patients, caregivers and healthcare professionals.